Türkiye Change Country

Clinical Studies Supporting KCI Proprietary V.A.C. Therapy System

Released : 23 Nisan 2009

SAN ANTONIO, TX -- April 23, 2009 -- Kinetic Concepts, Inc. today announced that oral and poster presentations supporting the use of its V.A.C.® Therapy will be given at the 22nd Symposium on Advanced Wound Care/Wound Healing Society Meeting, April 26-29 in Dallas.

Two studies were accepted for oral presentation, with one ranking third among the top three selected for oral presentation at the symposium.

This study, reporting the healthcare utilization, hospitalization and surgical procedure cost differences between the use of KCI’s proprietary V.A.C. Therapy versus Advanced Moist Wound Therapy (AMWT) in patients with diabetic foot ulcers (DFUs), will be presented by Vickie R. Driver, DPM, MS, FACFAS. Dr. Driver is associate professor of surgery at Boston University School of Medicine and Director, Clinical Research, Endovascular and Vascular and Foot Care Specialists, and Director of the Research Fellowship Program at Boston Medical Center. The study is one of four oral abstracts that will be presented during Session 42 on Tuesday, April 28, 2:15 p.m. - 3:15 p.m. CST at the Gaylord Texan Hotel and Convention Center.

Dr. Driver analyzed the data from a multi-center, 342-patient randomized clinical trial (RCT) that assessed the efficacy and safety of negative wound pressure therapy using reticulated open cell foam (NPWT/ROCF) as delivered by V.A.C. Therapy comparatively to AMWT in adult patients with diabetic foot ulcers.

“The study found that during the active treatment phase [112 days] of the RCT, patients with DFUs treated with V.A.C. Therapy had fewer hospital admissions and amputations,” said Dr. Driver. “This resulted in lower costs related to hospitalizations and surgical procedures compared to patients treated with AMWT.”

The researchers on this study included Charles Anderson, M.D., Gerry Oster, Ph.D., and Charu Taneja, MPH.

Based on her study’s ranking, Dr. Driver will receive an award at the poster gala to be held during the symposium. Clinical research abstracts submitted to SAWC are scored based on the following criteria: objectives, materials and methods; study design; stated findings; and important outcomes and findings.

An additional abstract on NPWT using V.A.C. Therapy was selected for oral presentation. Michael N. Desvigne, M.D., FACS will present “Early Intervention Using Negative Pressure Wound Therapy: Does It Make a Difference in Compartment Syndrome?” This retrospective review of 8 patients indicated that early initiation of V.A.C. Therapy in study patients with compartment syndrome requiring fasciotomy may enhance limb salvage by reducing edema and promoting perfusion.

Nine posters reporting the results of studies evaluating the use of KCI’s proprietary V.A.C. Therapy system to bolster split thickness skin grafts and to treat pressure ulcers, diabetic foot ulcers and other wounds will also be presented at SAWC. They consist of the following:

  • Improving Split Thickness Skin Graft Take with V.A.C. Therapy -- B. Bernstein, A. Williams, V. Driver
  • Staged Surgical Closure in Combination with V.A.C. Therapy Increases Closure Success of Stage III and IV Pressure Ulcers -- G. Powell, F. Pelham
  • Pediatric Wounds on the Foot Respond Favorably to V.A.C. Therapy -- A. Gabriel, D. Daly, S. Gupta
  • Negative Pressure Wound Therapy in the Management of Diabetic Foot Ulcers for Managed Care Patients – A. Gabriel, S. Gupta
  • Effectiveness of V.A.C. Therapy in the Management of the Traumatic Open Abdomen -- M. Kaplan, J. Leibman, N. Jones, A. Hooper, L. Conrad, H. Simms
  • Use of V.A.C. Therapy for Delayed Primary Closure of Fasciotomy Wounds: A Retrospective Review -- M. Gillespie, R. Puri, M. Kaplan, Albert Einstein Medical Center
  • Early Intervention Using V.A.C. Therapy: Does It Make a Difference in Necrotizing Soft Tissue Infection -- M. Desvigne, K. Grant, P. Downs, Banner Boswell Wound Center
  • Early Use of V.A.C. Therapy in the Open Abdomen: Improved Outcomes with Reduced Times to Closure and Reduced Complications -- M. Kaplan, J. Leibman, N. Jones, A. Hooper, L. Conrad, H. Simms
  • Early Intervention Using V.A.C. Therapy: Does It Make a Difference in Surgical Wounds? -- M. Desvigne, K. Grant, P. Downs, Banner Boswell Wound Center

“The data that will be presented at the Symposium on Advanced Wound Care adds to the extensive body of evidence supporting the clinical benefits of V.A.C. Therapy in treating the most serious wounds,” said Dr. Gilles Delecoeuillerie, Vice President of Global Medical Affairs and Clinical Sciences for KCI. “As a global leader in advanced wound care, KCI encourages research that complements the already impressive amount of scientific knowledge on V.A.C. Therapy.”

In addition, a symposium, “Understanding the Cost of Wound Care and Its Impact on Clinical Outcomes,” will be presented at the conference Sunday, April 26, 12:30 p.m. – 2:00 p.m. CST. The symposium will feature Dr. Caroline Fife, Director of Clinical Research at Memorial Hermann Center for Wound Healing & Hyperbaric Medicine and Chief Medical Officer for Intellicure, and Dr. Vickie Driver.

Dr. Fife will discuss the prevalence of wounds and the staggering cost impact to treat them. She will also describe the role of randomized clinical trials (RCTs) in guiding clinical decision-making and how large clinical data sets across diverse patient populations can augment and enhance clinical decision making in therapy choice. Dr. Driver will discuss cost effective approaches to wound care, their utilization and the economic impact of advanced wound healing technologies such as V.A.C. Therapy as well as conservative therapy.

About KCI

Kinetic Concepts, Inc. is a leading global medical technology company devoted to the discovery, development, manufacture and marketing of innovative, high-technology therapies and products for the wound care, tissue regeneration and therapeutic support system markets. Headquartered in San Antonio, Texas, KCI's success spans more than three decades and can be traced to a history deeply rooted in innovation and a passion for significantly improving the healing - and the lives - of patients around the world.

KCI's three primary businesses include:

Advanced Wound Care - Includes KCI's proprietary Vacuum Assisted Closure, or V.A.C. Therapy System, which has been clinically demonstrated to promote wound healing through unique mechanisms of action while reducing the overall cost of treating patients with complex wounds.

Regenerative Medicine - Represented by KCI's LifeCell business and includes tissue-based products for use in reconstructive, orthopedic and urogynecologic surgical procedures to repair soft tissue defects.

Therapeutic Support Systems - Includes specialty hospital beds, mattress replacement systems and overlays designed to address pulmonary complications associated with immobility, to reduce skin breakdown and assist caregivers in the safe and dignified handling of patients of size.

The Company employs approximately 6,700 people and markets its products in more than 20 countries. For more information about KCI, and how its products are changing the practice of medicine, visit www.KCI1.com.

FOR MORE INFORMATION, CONTACT:

Kinetic Concepts, Inc.
Media Relations:
Media@kci1.com for journalists only.
or
Investors Relations:
IR@kci1.com for Investor Relations inquiries.


Hastalara Yönelik Önemli Mesaj

Yasal Uyarı | Gizlilik Politikası | Bize Ulaşın


Telif Hakkı © 1998 – 2013 KCI Licensing, Inc Tüm Hakları Saklıdır.     DSL#12-0298.TR
Bu Web sitesinde yer alan bilgiler yalnızca Türkiye'de görüntülenecek şekilde ve bu amaçla hazırlanmışlardır. Bu Web sitesi, farklı ülkelerde bulunan veya bulunmayan ve mümkünse, farklı ülkelerde farklı göstergeler ve sınırlamalar için bir düzenleyici makam tarafından onay veya izin almış ya da almamış olan ürünler hakkında bilgiler içerir.